Responses to imatinib vs. interferon + cytarabine in newly diagnosed CML patients in chronic phase
| Complete Hematological Response | Major Cytogenetic Response | Complete Cytogenetic Response | Progression-Free Survival (14 months) | |
|---|---|---|---|---|
| % | ||||
| Imatinib (n = 553) | 95.3 | 85.2 | 73.8 | 92.1 |
| Interferon-α + cytarabin (n = 553) | 55.5 | 22.1 | 8.5 | 73.5 |
| p = | 0.001 | 0.001 | 0.001 | 0.001 |
Median duration of follow-up = 19 months.